Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Inclusion Criteria: * Single or bilateral lung transplant recipients * Confirmed RSV infection * Greater than 90 days post current lung transplant * Rejection free for a minimum of 30 days Exclusion Criteria: * Known viral, bacterial, or fungal respiratory co-infection at the time of RSV diagnosis * Bronchiolitis obliterans syndrome (BOS) Grade 3 or any BOS with FEV1 that has not been stable for at least 3 months * Use of alemtuzumab within 9 months prior to screening, anti-thymocyte globulin (ATG) within 90 days of screening or prednisone or equivalent as maintenance therapy * Active treatment for acute graft rejection